AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
LakeShore Biopharma received a letter from Nasdaq stating that the company is not in compliance with Nasdaq Listing Rule 5550(a)(2 due to its closing bid price being below $1.00 per share for 30 consecutive business days. The company is ineligible for the standard 180-day compliance period and must submit a plan to regain compliance within 45 days.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet